These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24901294)

  • 21. Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
    Papp-Wallace KM; Taracila M; Hornick JM; Hujer AM; Hujer KM; Distler AM; Endimiani A; Bonomo RA
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2867-77. PubMed ID: 20421396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. "Mind the Gap": Raman Evidence for Rapid Inactivation of CTX-M-9 β-Lactamase Using Mechanism-Based Inhibitors that Bridge the Active Site.
    Heidari-Torkabadi H; Bethel CR; Ding Z; Pusztai-Carey M; Bonnet R; Bonomo RA; Carey PR
    J Am Chem Soc; 2015 Oct; 137(40):12760-3. PubMed ID: 26421661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical inhibitor-resistant mutants of the beta-lactamase TEM-1 at amino-acid position 69. Kinetic analysis and molecular modelling.
    Chaibi EB; Péduzzi J; Farzaneh S; Barthélémy M; Sirot D; Labia R
    Biochim Biophys Acta; 1998 Jan; 1382(1):38-46. PubMed ID: 9507060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sulbactam forms only minimal amounts of irreversible acrylate-enzyme with SHV-1 beta-lactamase.
    Totir MA; Helfand MS; Carey MP; Sheri A; Buynak JD; Bonomo RA; Carey PR
    Biochemistry; 2007 Aug; 46(31):8980-7. PubMed ID: 17630699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of TEM-2 beta-lactamase from Escherichia coli by clavulanic acid: observation of intermediates by electrospray ionization mass spectrometry.
    Brown RP; Aplin RT; Schofield CJ
    Biochemistry; 1996 Sep; 35(38):12421-32. PubMed ID: 8823177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unusual tazobactam-sensitive AmpC beta-lactamase from two Escherichia coli isolates.
    Babini GS; Danel F; Munro SD; Micklesen PA; Livermore DM
    J Antimicrob Chemother; 1998 Jan; 41(1):115-8. PubMed ID: 9511046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli to 12 beta-lactam agents and combinations with beta-lactamase inhibitors.
    Tajada P; Gomez-Graces JL; Alós JI; Balas D; Cogollos R
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1924-5. PubMed ID: 8843305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 beta-lactamases.
    Giakkoupi P; Tzelepi E; Legakis NJ; Tzouvelekis LS
    J Antimicrob Chemother; 1999 Jan; 43(1):23-9. PubMed ID: 10381097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
    Kuck NA; Jacobus NV; Petersen PJ; Weiss WJ; Testa RT
    Antimicrob Agents Chemother; 1989 Nov; 33(11):1964-9. PubMed ID: 2558615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protection of piperacillin and ticarcillin from beta-lactamase hydrolysis by tazobactam (YTR-830) and clavulanic acid.
    Diver JM; Thornber D; Wise R
    J Antimicrob Chemother; 1989 Jul; 24(1):89-92. PubMed ID: 2550415
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of pH on activities of novel beta-lactamases and beta-lactamase inhibitors against these beta-lactamases.
    Ohsuka S; Arakawa Y; Horii T; Ito H; Ohta M
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1856-8. PubMed ID: 7486932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Post-β-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extended-spectrum-β-lactamase-producing strains.
    Sader HS; Rhomberg PR; Jones RN
    Antimicrob Agents Chemother; 2014; 58(4):2434-7. PubMed ID: 24449780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative in-vitro activities of GD-40 and other beta-lactamase inhibitors against TEM-1 and SHV-2 beta-lactamases.
    Danelon G; Mascaretti O; Radice M; Power P; Calcagno ML; Mata EG; Gutkind G
    J Antimicrob Chemother; 1998 Feb; 41(2):313-5. PubMed ID: 9533481
    [No Abstract]   [Full Text] [Related]  

  • 34. Selection of variants of the TEM-1 beta-lactamase, encoded by a plasmid of clinical origin, with increased resistance to beta-lactamase inhibitors.
    Thomson CJ; Amyes SG
    J Antimicrob Chemother; 1993 May; 31(5):655-64. PubMed ID: 8392995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interaction between class B beta-lactamases and suicide substrates of active-site serine beta-lactamases.
    Prosperi-Meys C; Llabres G; de Seny D; Soto RP; Valladares MH; Laraki N; Frere JM; Galleni M
    FEBS Lett; 1999 Jan; 443(2):109-11. PubMed ID: 9989585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kinetic analysis of an inhibitor-resistant variant of the OHIO-1 beta-lactamase, an SHV-family class A enzyme.
    Lin S; Thomas M; Shlaes DM; Rudin SD; Knox JR; Anderson V; Bonomo RA
    Biochem J; 1998 Jul; 333 ( Pt 2)(Pt 2):395-400. PubMed ID: 9735103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.
    Piddock LJ; Jin YF; Turner HL
    J Antimicrob Chemother; 1993 Jan; 31(1):89-103. PubMed ID: 8383105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
    Fonseca F; Sarmento AC; Henriques I; Samyn B; van Beeumen J; Domingues P; Domingues MR; Saavedra MJ; Correia A
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4512-4. PubMed ID: 17875998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A kinetic study of NMC-A beta-lactamase, an Ambler class A carbapenemase also hydrolyzing cephamycins.
    Mariotte-Boyer S; Nicolas-Chanoine MH; Labia R
    FEMS Microbiol Lett; 1996 Sep; 143(1):29-33. PubMed ID: 8807798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ligand-dependent disorder of the Omega loop observed in extended-spectrum SHV-type beta-lactamase.
    Sampson JM; Ke W; Bethel CR; Pagadala SR; Nottingham MD; Bonomo RA; Buynak JD; van den Akker F
    Antimicrob Agents Chemother; 2011 May; 55(5):2303-9. PubMed ID: 21357298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.